Antiemetics And Antinauseants Market Report 2026

Antiemetics And Antinauseants Market Overview

• Antiemetics And Antinauseants market size has reached to $8.48 billion in 2025 • Expected to grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 3.5% • Growth Driver: Rising Tuberculosis Prevalence Drives Growth In Antiemetics And Antinauseants Market • Market Trend: Amneal Pharmaceuticals Launches FOCINVEZ: A Game-Changer In Ready-To-Use Antiemetic Injectable Formulations • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Antiemetics And Antinauseants Market?

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes.

What Is The Antiemetics And Antinauseants Market Growth Forecast?

The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to increasing prevalence of motion sickness, growth in global geriatric population, rising adoption of personalized medicine, innovations in novel antiemetic drug delivery systems, expansion of outpatient chemotherapy and palliative care services. Major trends in the forecast period include personalized anti-nausea therapy development, novel drug delivery systems, combination therapy approaches, rising demand for chemotherapy supportive care, growth in motion sickness and travel-related treatments.

Global Antiemetics And Antinauseants Market Segmentation

1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes Subsegments: 1) By Dopamine Antagonists: Metoclopramide, Prochlorperazine, Domperidone 2) By NK1 Receptor Antagonists: Aprepitant, Fosaprepitant, Rolapitant 3) By Antihistamines (H1 Histamine Receptor Antagonists): Dimenhydrinate, Meclizine, Diphenhydramine 4) By Cannabinoids: Dronabinol, Nabilone 5) By Benzodiazepines: Lorazepam, Diazepam 6) By Anticholinergics: Scopolamine, Glycopyrrolate 7) By Steroids: Dexamethasone, Methylprednisolone 8) By 5-HT3 Receptor Antagonists: Ondansetron, Granisetron, Palonosetron 9) By Other Drug Types: Herbal Remedies, Acupressure Devices

What Are The Drivers Of The Antiemetics And Antinauseants Market?

Increased prevalence of tuberculosis is expected to propel the growth of antiemetics and antinauseants market. Tuberculosis (TB) is an infectious bacterial disease primarily impacting the lungs. Antiemetics and antinauseants are employed for the purpose of controlling nausea and vomiting induced by anti-tuberculosis medications. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal agency, in 2024, a provisional total of 10,347 tuberculosis cases were reported in the United States, corresponding to a rate of 3.0 cases per 100,000 population an increase of approximately 8% compared with 2023. Therefore, the increased prevalence of tuberculosis is expected to propel the growth of antiemetics and antinauseants industry. The increasing number of surgeries is expected to propel the growth of the antiemetic and antinauseant market going forward. Surgery is a medical procedure in which doctors use instruments to treat injuries, diseases, or conditions by cutting into the body or repairing internal tissues and organs. Surgery is rising due to the growing prevalence of chronic diseases that often require operative treatment. Antiemetic and antinauseant drugs are used in surgeries to prevent or reduce postoperative nausea and vomiting caused by anesthesia and surgical procedures. For instance, in April 2025, according to the Australian Institute of Health and Welfare, an Australia-based government organization, reported that in 2023–24, public hospitals recorded 778,500 admissions from elective surgery waitlists, marking a 5.8% rise compared with 735,500 admissions in 2022–23. Therefore, the increasing number of surgeries is driving the growth of the antiemetic and antinauseant market.

Key Players In The Global Antiemetics And Antinauseants Market

Major companies operating in the antiemetics and antinauseants market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA

Global Antiemetics And Antinauseants Market Trends and Insights

Major companies operating in the antiemetic and antinauseant markets are working on new product innovations, such as ready-to-use injectables, to streamline treatment processes and enhance patient compliance. These ready-to-use formulations are designed to provide immediate effectiveness, reducing the time and complexity associated with traditional injectable medications. For instance, in July 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FOCINVEZ, the first ready-to-use injectable formulation of fosaprepitant, designed to prevent acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy. This product is available in a 150 mg/50 mL vial, free of Polysorbate 80, and does not require reconstitution or dilution, allowing for direct administration. FOCINVEZ is approved for use in adults and pediatric patients aged six months and older and has been assigned a unique J-Code (J1434) for reimbursement.

Regional Insights

North America was the largest region in the drugs for antiemetics and antinauseants market in 2025. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antiemetics And Antinauseants Market?

The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antiemetics And Antinauseants Market Report 2026?

The antiemetics and antinauseants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.